Myocardial angiogenesis mediated by human vascular endothelial growth factor 165 (hVEGF 165 ) cDNA was promoted in rat myocardium using an in vivo-targeted gene delivery system known as ultrasound-targeted microbubble destruction (UTMD). Microbubbles carrying plasmids encoding hVEGF 165 , or control solutions were infused intravenously during ultrasonic destruction of the microbubbles within the myocardium. Biochemical and histological assessment of gene expression and angiogenesis were performed 5, 10, and 30 days after UTMD. UTMD-treated myocardium contained hVEGF 165 protein and mRNA. The myocardium of UTMD-treated animals showed hypercellular foci associated with hVEGF 165 expression and endothelial cell markers. Capillary density in UTMD-treated rats increased 18% at 5 days and 33% at 10 days, returning to control levels at 30 days (Po0.0001). Similarly, arteriolar density increased 22% at 5 days, 86% at 10 days, and 31% at 30 days (Po0.0001). Thus, noninvasive delivery of hVEGF 165 to rat myocardium by UTMD resulted in significant increases in myocardial capillary and arteriolar density.
Introduction
The stimulation of new blood vessel growth by vascular growth factors and/or the genes that express them has long been proposed as a potential treatment for myocardial ischemia. [1] [2] [3] [4] Although great strides have been made in our understanding of the biology of angiogenesis (development of new capillaries) and arteriogenesis (development of larger vessels containing an intima, media, and adventitia), translation of the basic science into clinically useful therapies has not yet occurred. Simons and Ware 4 have pointed out that the largely disappointing results of recent clinical trials of angiogenic therapies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] can be explained by a variety of factors, including patient selection, incomplete understanding of the optimal angiogenic agent or combination of agents, a limited time course of treatment (usually a single fixed dose), and suboptimal delivery techniques. The latter two issues are inter-related in that current methods of delivering angiogenic agents are limited to direct myocardial injection or intracoronary infusion, invasive techniques that are not well suited for repeated treatments.
We propose a new noninvasive method, ultrasoundtargeted microbubble destruction (UTMD), that allows specific targeting of gene therapy to the heart. Briefly, cationic liposomes containing plasmid DNA are attached to the phospholipid shell of gas-filled microbubbles 2-4 mm in diameter. These microbubble-liposome complexes are infused intravenously (i.v.) and destroyed within the myocardial microcirculation by low-frequency ultrasound. We have previously shown that UTMD can be used to deliver reporter genes selectively to the heart; [15] [16] [17] however, there have been no reports of its use to achieve a biological effect. Here, we examine whether UTMD can promote angiogenesis by noninvasive delivery of the human vascular endothelial growth factor 165 (hVEGF 165 ) expression construct to rat myocardium.
Results
Male Sprague-Dawley rats underwent UTMD treatment with microbubbles containing a plasmid encoding the hVEGF 165 gene, or three different controls: hVEGF 165 plasmid without microbubbles, microbubbles alone without plasmid, or saline. All rats tolerated the UTMD procedure without complications and survived to their designated sacrifice at either 5, 10, or 30 days after the procedure. Left ventricular mass and fractional area shortening showed no significant difference between UTMD-treated or control rats ( Table 1 ), suggesting that left ventricular hypertrophy or systolic dysfunction did not occur as a result of UTMD. At the time of killing, animals exhibited no changes in activity or feeding, and lacked any evidence of edema, hemangioma, or other tumors.
Presence of hVEGF 165 in rat myocardium
Immunoblotting revealed a prominent 37 kDa band consistent with hVEGF 165 in homogenates of cardiac tissue 10 days after treatment ( Figure 1 ). Faint bands, probably representing endogenous vascular endothelial growth factor (VEGF), were seen in control animals. Increases in hVEGF 165 protein were restricted to the tissue targeted by UTMD. Homogenates of organs that lie adjacent to, but outside the region of ultrasound targeting, such as liver, lung and spleen, showed no similar increase in hVEGF 165 protein. These findings confirm tissue specificity of the exogeneous angiogenic gene that was restricted to the insonified region. hVEGF 165 was not detected in any control animals.
Consistent with the results of Western blots, RT-PCR revealed expression of hVEGF 165 in day 5 and day 10 groups as well as one rat in day 30 group (Figure 2 ), but not in control groups. To avoid any cross contamination, no PCR-positive control was used for hVEGF 165 . Human VEGF 165 RT-PCR products were confirmed by sequencing (data not shown).
Histology
At 10 days post-treatment, histology revealed hypercellular foci in the myocardium of UTMD-treated animals ( Figure 3 ), but not in control animals. These hypercellular foci showed staining with anti-VEGF antibody, confirming successful transfer and expression of the exogenous angiogenic gene. In addition, these foci showed staining with the endothelial cell-specific markers CD-31 and BS-I lectin. Endothelial cells in these regions displayed prominent nuclei and occasional mitotic figures. Smooth muscle a-actin staining showed pericytes covering the vessels, which is further evidence for angiogenesis. Neutrophils, monocytes, plasma cells, and lymphocytes were distinctly rare and there was no myocyte necrosis. However, there was fibroblast prolif- Figure 1 Immunoblotting for the presence of hVEGF 165 protein in tissue homogenates from rat myocardium. Prominent bands consistent with hVEGF 165 are seen in all three rats treated with UTMD-hVEGF 165 at day 10, but only a faint band is seen in control rats (UTMD alone, hVEGF165 plasmid alone, or saline). A positive control band is also shown (+C). Targeted VEGF delivery to myocardium G Korpanty et al eration with disorganization of the myofibrillar architecture, consistent with mild inflammation. By day 30, these foci exhibited resolution of the inflammation. None of these hypercellular foci were present in any control animal. Myocardial capillary density was assessed histologically using BS-1 lectin staining ( Figure 4 , top panels). Capillary density was remarkably similar in the three control groups over all three time periods, averaging 26067150/mm 2 ( Figure 4 , bottom panel). In the UTMDtreated rats, capillary density was increased by 18% at day 5 (3079786/mm 2 ) and 33% at day 10 (34657283/ mm 2 ), but returned to control levels at day 30 (26837145/mm 2 ). By ANOVA, the change in capillary density between treatment groups was statistically significant (F ¼ 19.25, Po0.0001).
Arteriolar density was assessed using smooth muscle a-actin (sm-a-actin) staining ( Figure 5 , top panels). Arteriolar density was not significantly different between control groups at the three time points studied, averaging 71710/mm 2 ( Figure 5 , bottom panel). In UTMDtreated rats, arteriolar density was increased by 23% at day 5 (8773/mm 2 ), 86% at day 10 (132743/mm 2 ), and 31% at day 30 (9377/mm 2 ). By ANOVA, the change in arteriolar density between treatment groups was statistically significant (F ¼ 11.05, Po0.0001).
Discussion
The major finding in this study is that an angiogenic gene can be targeted noninvasively to the heart, and can modify the myocardial microvasculature. Specifically, there was a transient elevation in capillary density and a more sustained elevation in arteriolar density. Notably, this is the first evidence that noninvasive delivery of a transgene to the heart has therapeutic potential in that it results in both gene expression and biological changes in the myocardium.
In our study, we were able to show increased capillary and arteriolar density within the myocardium after hVEGF 165 plasmid gene transfer. Limited plasmid expression (hVEGF 165 protein was detectable in all treated rats only at day 10 after gene delivery) increased both capillary and arteriolar density at 10 days of treatment. However, by day 30, regression of capillary density to the baseline level was observed. Perhaps this is due to the transient nature of the plasmid expression or subsequent capillary derecruitment in the setting of normal rather than ischemic myocardium.
Arterioles also decreased from their peak at day 10 by day 30 post-treatment. However, the 30-day arteriolar density was still significantly higher than in controls, indicating sustained arteriogenesis after hVEGF 165 therapy. This is an important new finding that may be related to the longer expression of hVEGF 165 after UTMD than with direct injection or intracoronary infusion. In a murine model of conditional switching of VEGF, brief exposure to VEGF causes transient growth of vessels that disappear after VEGF withdrawal. 18 In contrast, 10-14 days of VEGF stimulation produced an arteriogenic response in which mature vessels did not resorb. 18 In our study, UTMD resulted in readily detectable hVEGF 165 protein by Western blots in the rat myocardium 10 days after treatment. The prolonged duration of hVEGF 165 Targeted VEGF delivery to myocardium G Korpanty et al expression with UTMD may also facilitate the previously described protective effect of smooth muscle cellendothelial cell interactions on the newly formed microcirculation and its important role in the vascular remodeling. [19] [20] [21] [22] We did not observe any increase in capillary or arteriolar density with either hVEGF 165 plasmid alone, or with microbubble destruction alone. It is not surprising that i.v. VEGF does not promote angiogenesis because of the effects of circulating DNases and the absence of a mechanism for the circulating plasmid to cross the endothelial barrier. However, Song et al 23 demonstrated arteriogenesis in rat skeletal muscle exposed to the low-frequency ultrasound after intravenous injection of albumin microbubbles, suggesting that microbubble destruction may contribute to vascular remodeling. Ultrasonic microbubble destruction is known to cause cavitation, thermal effects, microstreaming, and free radical production, factors that could potentially interact with endothelial cells, leading to their activation. [24] [25] [26] [27] Also, mechanical destruction of the microbubbles within the microvasculature creates capillary ruptures; 28, 29 healing of these rupture sites may have contributed to some aspect of arteriogenesis in their model. The absence of an angiogenic effect of UTMD alone in our study could be due to different responses to microbubble destruction in the myocardium compared to skeletal muscle, differences between albumin and lipid microbubble shells, or other unknown experimental variables.
The mild inflammation and disruption of myocellular architecture noted in the UTMD group is likely a result of VEGF-mediated angiogenesis by UTMD. VEGF is known to promote inflammation via several mechanisms, including endothelial cell adhesion markers, matrix metalloproteinases, and a-defensins. [30] [31] [32] The absence of these histologic findings in the control groups indicates that destruction of the microbubbles alone was not sufficient to cause inflammation, nor was the infusion of VEGF plasmid alone, without microbubble carriers. However, it is possible that a combination of VEGF plasmid and microbubble destruction is synergistic in producing an inflammatory response. It is important to note that this inflammatory response did not result in left ventricular hypertrophy or systolic dysfunction, confirming results of our previous study on the lack of significant bioeffects of microbubble destruction in the heart. 33 We have also shown that microbubble destruction, at a similar microbubble concentration and sonographic power used here, does not induce cardiac gene expression in vivo. 34 Finally, in previous studies using reporter genes delivered to the heart by UTMD, we did not find any evidence of inflammation by histology 33 or gene expression. 34 
Limitations
This study demonstrates that UTMD delivery of an hVEGF 165 expression construct can stimulate capillary and arteriolar growth in normal myocardium. Further studies in ischemic myocardium are needed. Owing to Targeted VEGF delivery to myocardium G Korpanty et al the requirement for histological evaluation, we only examined the effects of UTMD on blood vessel growth at three specific time points -days 5, 10, and 30. Therefore, we have not established the timing or maximal amount of transgene expression, nor the maximal amount of capillary or arteriolar response at intermediate time points. Similarly, we do not know if, after 30 days, arteriolar density returns to the baseline level or whether hypoxic conditions can sustain the arteriogenesis process as described by Hershey et al, 35 in the rabbit hindlimb ischemia model. We have previously shown that the expression of a reporter construct in the heart can be prolonged by repeated application of UTMD. 17 Arteriogenesis can be caused by growth of pre-existing small capillaries 36 or de novo formation of new arterioles. 37 We have not determined the contribution of either or both of these mechanisms in this model. There are a number of other known angiogenic factors, such as fibroblast growth factors (FGF), platelet-derived growth factors (PDGF), angiopoetin-2, or hypoxia-inducible factor 1-a (HIF-1a), 38 that could produce superior angiogenic or arteriogenic responses with UTMD, perhaps without some of the inflammatory consequences of VGEF. It should also be noted that angiogenesis in the vasa vasorum might promote or facilitate atherosclerosis, [39] [40] [41] a potential adverse effect of VEGF-gene therapy that was not addressed in this study.
Finally, we have not tested the ability of UTMD to deliver genes successfully to the hearts of larger mammals, such as dogs or pigs. The small size of the rats may make them more suitable for UTMD because the heart is small enough to be fully encompassed by the width of the ultrasound beam and because there is less tissue attenuation or lung interference.
Conclusions
UTMD directs hVEGF 165 expression to rat myocardium, with resultant increases in both capillary and arteriolar density. This method is noninvasive and allows specific targeting of gene expression to the heart and other organs. It also appears to be safe with no detrimental effect on left ventricle (LV) function. The exact molecular mechanism of myocardial transfection by UTMD remains to be determined.
Materials and methods

Animal preparation and gene delivery
Animal studies were performed in accordance with NIH recommendations and the approval of the institutional animal research committee. Male Sprague-Dawley rats (200-250 g, Harlan) were anesthetized with intraperitoneal ketamine (60 mg/kg) and xylazine (5 mg/kg). Hair was shaved from the precordium and neck, and a polyethylene tube (PE 50, Becton Dickinson, MD, USA) was inserted into the right internal jugular vein by cutdown. Rats received one of four treatments: microbubbles loaded with plasmids encoding the hVEGF 165 gene under an enhanced CMV promoter (0.6 mg DNA/kg), Targeted VEGF delivery to myocardium G Korpanty et al these same plasmids (0.6 mg/kg) unattached to microbubbles, microbubbles alone without attached plasmids, or normal saline. Animals that received bubble solutions had 0.5 ml bubbles mixed with 0.5 ml of PBS infused over 20 min via pump (Genie, Kent Scientific). In all, 1 ml of the nonbubble plasmid or saline solution was similarly infused undiluted for a total of 1 ml over 20 min.
During the infusion, ultrasound was directed to the heart using a commercially available ultrasound transducer (S3, Sonos 5500, Philips Ultrasound, Bothell, WA, USA). A mid-ventricular, short axis view of the heart was obtained and after optimization of the image plane, the probe was clamped in place. Ultrasound was then applied in ultraharmonic mode (transmit 1.3 MHz/ receive 3.6 MHz) at a mechanical index of 1.6. Four bursts of ultrasound were triggered to every fourth endsystole by ECG using a delay of 45-70 ms after the peak of the R wave. These settings have been shown to be optimal for plasmid delivery by UTMD using this instrument. 16 Bubble destruction was visually apparent in all rats. The echo-contrast signal was visually absent in the myocardium by the fourth pulsation. After UTMD, the jugular vein was tied off, the skin closed, and the animals were allowed to recover. Animals were killed at day 5 (n ¼ 12), day 10 (n ¼ 12), or day 30 (n ¼ 12) after UTMD using an overdose of sodium pentobarbital (120 mg/kg). These time points were chosen based on our previous findings of reporter gene expression after UTMD. 16, 17 The heart, lung, liver, spleen and kidney were harvested for histology and assessment of hVEGF 165 protein by Western blot and and mRNA by RT-PCR.
Immunohistochemistry
The harvested tissues were fixed in methyl carnosyl and then 70% ethanol and embedded in paraffin. In all, 5 mm sections were obtained, deparaffinized, and subjected to antigen retrieval for CD31, hVEGF 165 , and smooth muscle a-actin by microwave heating for 20 min at 900 W in 0.01 M sodium citrate, pH 6.0. Sections were blocked with 10% goat serum and endogenous peroxidase activity was quenched with 0.3% H 2 O 2 in methanol. Sections were incubated with primary monoclonal antibodies according to the manufacturer's recommendations: anti-CD31 at 1:50 dilution, anti-smooth muscle a-actin at 1:20 dilution, and anti-human VEGF-165 at 1:100 dilution, followed by biotinylated secondary antibodies: anti-mouse IgG for CD31 and smooth muscle a-actin and anti-goat IgG for VEGF. Lectin stains were performed with Griffonia simplicifolia agglutinin I: BS-I lectin biotinylated antibody (Sigma-Aldrich, St Louis, MO, USA) without antigen retrieval after blocking with 10% goat serum and quenching as above. All stains were developed with HRP-streptavidin followed by DAB chromogen and counterstained with hematoxylin.
RT-PCR
Total RNA was prepared from the specimens using an RNeasy Mini Kit (QIAGEN) according to the manufacturer's instructions. cDNA synthesis was carried out in a total 20 ml reaction with 30 ng of total RNA using a Sensiscript RT Kit (QIAGEN). PCR was performed for all samples using a GeneAmp PCR System 9700 (PE ABI) in 50 ml volume containing 2 ml cDNA, 25 ml of HotStarTaq 
VEGF Western blot
Equal amounts of protein from tissue homogenates harvested at each time point (5, 10, and 30 days) after gene delivery were subjected to electrophoresis through a 12% SDS polyacrylamide gel and transferred to a polyvinylidene fluoride membrane (Immobilon, Millipore, Billerica, MA, USA), blocked, and incubated with anti-human-VEGF antibody. Immunoreactive bands were visualized with chemiluminescent substrate (ECL, Amersham, Piscataway, NJ, USA).
Capillary and arteriolar density measurement
BS-I lectin positive vessels with a diameter of o10 mm and smooth muscle a-actin-positive vessels with a diameter of 430 mm visualized by immunohistochemistry were considered as capillaries and arterioles, respectively. Capillaries were counted by the use of light microscopy at a magnification of Â 400. Five photomicrographs were taken from each slide and a grid was placed over each photomicrograph. Using a random number generator, five sections from each grid were selected for counting, giving a total of 25 fields per rat. Capillary density was expressed as the number per mm 2 .
Only sections oriented perpendicular to the vessels were counted. Arteriolar density was counted in a similar manner using a magnification of Â 200 because there are far fewer arterioles than capillaries. The investigator reading the capillary and arteriolar density was blinded to treatment group and time of killing.
Echocardiography
Echocardiographic measurements of LV mass and fractional area shortening were made from digital images acquired with a 12 MHz broadband transducer (S12 probe, Philips Ultrasound, Bothell, WA). LV mass was calculated by area-length method as follows:
where A 1 is the epicardial area and A 2 is the endocardial area obtained from short-axis views at end-diastole; L is the left ventricle (LV) length from the LV apex to the middle of the mitral annulus from long-axis views at end-diastole; t is the myocardial thickness back calculated from the short-axis cavity area.
Fractional area shortening was evaluated from the following formula:
where LVEDA is the left ventricle end-diastolic area (cm 2 ) and LVESA is the left ventricle end-systolic area (cm 2 ).
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Data analysis
Data were analyzed with Statview software (SAS, Cary, NC, USA). The results are expressed as mean7one standard deviation. Differences were analyzed by ANO-VA with Fisher's post hoc test and considered significant at Po0.05.
Manufacture of plasmid-containing lipid-stabilized microbubbles
Lipid-stabilized microbubbles were prepared as previously described in our laboratory. 16, 17 Briefly, a solution of DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine, Sigma, St Louis, MO, USA) 2.5 mg/ml; DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine (Sigma, St Louis, MO, USA) 0.5 mg/ml; and 10% glycerol was placed in 1.5 ml clear vials; the remaining headspace was filled with the perfluoropropane gas (Air Products, Inc, Allentown, PA, USA). Each vial was incubated at room temperature for 30 min and then mechanically shaken for 20 s by a dental amalgamator (Vialmixt, Bristol-Myers Squibb Medical Imaging, N Billerica, MA, USA). The lipid-stabilized microbubbles appear as a milky white suspension floating on the top of a layer of liquid. The liquid subnatant was discarded and the mean diameter and concentration of the microbubbles in the upper layer were measured by a particle counter (Beckman Coulter Multisizer III). Cationic liposomes containing plasmid DNA were made with 50 ml of cationic liposome solution (lipofectamine 2000, Invitrogen) mixed with 2 mg of plasmid DNA and incubated for 15 min at room temperature. This forms nanosphere-sized cationic liposome complexes encapsulating the plasmid DNA. 42 Microbubbles with the cationic liposome-plasmid complexes were made as above by adding 50 ml of liposomes to 250 ml of the phospholipid-coated microbubbles and shaking in the amalgamator for 20 s at room temperature with perfluoropropane gas filling the head space of the vial.
Plasmid constructs and DNA preparation
Plasmids expressing the hVEGF 165 gene under the enhanced CMV promoter with an intron were made as following:
Total mRNA was extracted from a healthy volunteer's blood with a QIAamp Blood kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's instructions. Then mRNA was reversed into cDNA with a SuperScript first-strand synthesis system for RT-PCR kit (Invitrogen). A full-length cDNA of the hVEGF 165 cDNA was PCR amplified by using the following PCR primers that contain a restriction site at the 5 0 ends (the restriction sites are underlined): The product was confirmed by sequencing. The DNA was digested with XhoI and SmaI and then ligated into the corresponding sites of pCI-neo (Promega). Cloning, isolation, and purification of this plasmid were performed by standard procedures, 42, 43 and once again sequenced to confirm that no artifactual mutations were present.
